meloxicam | Amelotex ampoules 15 mg, 1.5 ml, 5 pcs.
Special Price
$17.48
Regular Price
$28.00
In stock
SKU
BID464232
Release form
Intramuscular solution.
Intramuscular solution.
Release form
Intramuscular solution.
Packing
5 ampoules of 1.5 ml.
Pharmacological action
Amelotex is a non-steroidal anti-inflammatory drug that has anti-inflammatory, antipyretic, analgesic effects.
Selectively inhibits the enzymatic activity of cyclooxygenase-2. Suppresses the synthesis of prostaglandins in the area of inflammation to a greater extent than in the mucous membrane of the stomach or kidneys. Less commonly, it causes erosive and ulcerative lesions of the gastrointestinal tract.
The enolic acid derivative belongs to the class of oxycams.
Indications
Rheumatoid arthritis osteoarthritis ankylosing spondylitis (ankylosing spondylitis) inflammatory and degenerative joint diseases accompanied by pain.
Contraindications
Hypersensitivity to the active substance or auxiliary components
Contraindicated in the period after coronary artery bypass grafting
uncompensated heart failure
Complete or incomplete combination of bronchial asthma, non-relapsing syndrome and non-relapsing syndrome h in history)
Erosive-ulcerative changes in the gastric mucosa or duodenum, active gastrointestinal bleeding
Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
Cerebrovascular bleeding or other bleeding
Severe liver failure or active liver disease
Severe renal failure in patients not undergoing dialysis (creatinine clearance less than 30 ml / min), progressive kidney disease, including confirmed hyperkalemia
Pregnancy, breastfeeding
Children under 15 years of age.
Caution
To reduce the risk of developing adverse events, the minimum effective dose should be used with the smallest possible short course for coronary heart disease, cerebrovascular disease, congestive heart failure, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral artery disease, smoking, creatinine clearance less than 60 ml / min anamnestic data on the development of gastric ulcer, in the presence of Helicobacter pylori infection, in old age, with prolonged use of non-steroidal anti-inflammatory drugs, frequent alcohol consumption, severe somatic diseases, concomitant therapy with the following drugs: anticoagulants (e.g. warfarin), antiplatelet agents ( e.g. acetylsalicylic acid, clopidogrel), oral glucocorticosteroids (e.g. prednisone), selective serotonin reuptake inhibitors (e.g. Imer citalopram, fluoxetine, paroxetine, sertraline).
Special instructions
If peptic ulcers or gastrointestinal bleeding occurs, side effects of the skin and mucous membranes develop, the drug should be discontinued. In patients with a decrease in circulating blood volume and reduced glomerular filtration (dehydration, chronic heart failure, surgery), the appearance of clinically pronounced chronic renal failure, which is completely reversible after drug withdrawal (in such patients, diuresis and renal function should be monitored at the beginning of treatment) . With persistent and significant increase in transaminases and changes in other indicators of liver function, the drug should be discontinued and control tests performed. In patients with an increased risk of side effects, treatment begins with a dose of 7.5 mg. In the terminal stage of chronic renal failure in patients on dialysis, the dose should not exceed 7.5 mg / day. During the treatment period, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions (with the appearance of dizziness and drowsiness).
Composition
1 ampoule (1.5 ml) contains meloxicam as an active substance - 15 mg
excipients: meglumine, glycofurfural poloxamer 188, sodium chloride, glycerol, sodium hydroxide solution 1 M, water for injection.
Side effects of the
From the digestive system: nausea, vomiting, belching, abdominal pain, constipation or diarrhea, flatulence, increased activity of “liver” transaminases, hyperbilirubinemia, stomatitis, erosive and ulcerative lesions of the gastrointestinal tract, esophagitis, gastritis, colitis, perforation of the gastrointestinal tract, gastrointestinal bleeding (hidden or obvious), hepatitis.
From the nervous system: dizziness, vertigo, headache, tinnitus, confusion, drowsiness, disorientation, emotional lability.
From the respiratory system: bronchospasm.
From the hemopoietic organs: anemia, leukopenia, thrombocytopenia.
From the side of the cardiovascular system: peripheral edema, increased blood pressure, “flushes” of blood to the skin of the face and upper chest, palpitations.
From the urinary system: edema, hypercreatininemia, increased serum urea concentration. In rare cases, acute renal failure, interstitial nephritis, albuminuria, hematuria.
On the part of the sensory organs: conjunctivitis, visual impairment incl. blurred vision.
From the skin: itching, skin rash, urticaria, photosensitivity, bullous eruptions, erythema multiforme, toxic epidermal necrolysis.
Allergic reactions: angioedema, anaphylactoid, anaphylactic reactions.
Local reactions: burning and pain at the injection site are possible.
Storage conditions
In a dark place at a temperature of 8 to 25 РC.
active substance
Meloxicam
Terms and conditions
prescription
Dosage form
injection solution
Intramuscular solution.
Packing
5 ampoules of 1.5 ml.
Pharmacological action
Amelotex is a non-steroidal anti-inflammatory drug that has anti-inflammatory, antipyretic, analgesic effects.
Selectively inhibits the enzymatic activity of cyclooxygenase-2. Suppresses the synthesis of prostaglandins in the area of inflammation to a greater extent than in the mucous membrane of the stomach or kidneys. Less commonly, it causes erosive and ulcerative lesions of the gastrointestinal tract.
The enolic acid derivative belongs to the class of oxycams.
Indications
Rheumatoid arthritis osteoarthritis ankylosing spondylitis (ankylosing spondylitis) inflammatory and degenerative joint diseases accompanied by pain.
Contraindications
Hypersensitivity to the active substance or auxiliary components
Contraindicated in the period after coronary artery bypass grafting
uncompensated heart failure
Complete or incomplete combination of bronchial asthma, non-relapsing syndrome and non-relapsing syndrome h in history)
Erosive-ulcerative changes in the gastric mucosa or duodenum, active gastrointestinal bleeding
Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
Cerebrovascular bleeding or other bleeding
Severe liver failure or active liver disease
Severe renal failure in patients not undergoing dialysis (creatinine clearance less than 30 ml / min), progressive kidney disease, including confirmed hyperkalemia
Pregnancy, breastfeeding
Children under 15 years of age.
Caution
To reduce the risk of developing adverse events, the minimum effective dose should be used with the smallest possible short course for coronary heart disease, cerebrovascular disease, congestive heart failure, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral artery disease, smoking, creatinine clearance less than 60 ml / min anamnestic data on the development of gastric ulcer, in the presence of Helicobacter pylori infection, in old age, with prolonged use of non-steroidal anti-inflammatory drugs, frequent alcohol consumption, severe somatic diseases, concomitant therapy with the following drugs: anticoagulants (e.g. warfarin), antiplatelet agents ( e.g. acetylsalicylic acid, clopidogrel), oral glucocorticosteroids (e.g. prednisone), selective serotonin reuptake inhibitors (e.g. Imer citalopram, fluoxetine, paroxetine, sertraline).
Special instructions
If peptic ulcers or gastrointestinal bleeding occurs, side effects of the skin and mucous membranes develop, the drug should be discontinued. In patients with a decrease in circulating blood volume and reduced glomerular filtration (dehydration, chronic heart failure, surgery), the appearance of clinically pronounced chronic renal failure, which is completely reversible after drug withdrawal (in such patients, diuresis and renal function should be monitored at the beginning of treatment) . With persistent and significant increase in transaminases and changes in other indicators of liver function, the drug should be discontinued and control tests performed. In patients with an increased risk of side effects, treatment begins with a dose of 7.5 mg. In the terminal stage of chronic renal failure in patients on dialysis, the dose should not exceed 7.5 mg / day. During the treatment period, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions (with the appearance of dizziness and drowsiness).
Composition
1 ampoule (1.5 ml) contains meloxicam as an active substance - 15 mg
excipients: meglumine, glycofurfural poloxamer 188, sodium chloride, glycerol, sodium hydroxide solution 1 M, water for injection.
Side effects of the
From the digestive system: nausea, vomiting, belching, abdominal pain, constipation or diarrhea, flatulence, increased activity of “liver” transaminases, hyperbilirubinemia, stomatitis, erosive and ulcerative lesions of the gastrointestinal tract, esophagitis, gastritis, colitis, perforation of the gastrointestinal tract, gastrointestinal bleeding (hidden or obvious), hepatitis.
From the nervous system: dizziness, vertigo, headache, tinnitus, confusion, drowsiness, disorientation, emotional lability.
From the respiratory system: bronchospasm.
From the hemopoietic organs: anemia, leukopenia, thrombocytopenia.
From the side of the cardiovascular system: peripheral edema, increased blood pressure, “flushes” of blood to the skin of the face and upper chest, palpitations.
From the urinary system: edema, hypercreatininemia, increased serum urea concentration. In rare cases, acute renal failure, interstitial nephritis, albuminuria, hematuria.
On the part of the sensory organs: conjunctivitis, visual impairment incl. blurred vision.
From the skin: itching, skin rash, urticaria, photosensitivity, bullous eruptions, erythema multiforme, toxic epidermal necrolysis.
Allergic reactions: angioedema, anaphylactoid, anaphylactic reactions.
Local reactions: burning and pain at the injection site are possible.
Storage conditions
In a dark place at a temperature of 8 to 25 РC.
active substance
Meloxicam
Terms and conditions
prescription
Dosage form
injection solution
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review